60.66

0.60% 0.36

After Hours: 60.75 0.09 +0.15%

Bristol Myers Squibb Co (BMY)

Overview News Price History Option Chain Financials Why BMY Down? Discussions Forecast Stock Split Dividend History

Bristol Myers Squibb Co stock is traded at $60.66, with a volume of 9.60M. It is up +0.60% in the last 24 hours and up +11.88% over the past month. Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

Previous Close:

$60.30

Open:

$60.62

24h Volume:

9.60M

Relative Volume:

0.68

Market Cap:

$123.53B

Revenue:

$48.19B

Net Income/Loss:

$7.06B

P/E Ratio:

17.54

EPS:

3.4587

Net Cash Flow:

$12.85B

1W Performance:

-0.13%

1M Performance:

+11.88%

6M Performance:

+25.69%

1Y Performance:

+8.73%

1-Day Range:

$59.65

$60.93

1-Week Range:

$59.23

$61.30

52-Week Range:

$42.52

$63.33

Bristol Myers Squibb Co Stock (BMY) Company Profile

Name

Bristol Myers Squibb Co

Sector

Healthcare (1108)

Industry

Drug Manufacturers - General (20)

Phone

(609) 252-4621

Address

ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY

Employee

32,500

Twitter

@BMSNEWS

Next Earnings Date

2024-10-31

Latest SEC Filings

BMY's Discussions on Twitter

Compare BMY vs LLY, JNJ, ABBV, AZN, NVS

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BMY Bristol Myers Squibb Co	60.66	122.80B	48.19B	7.06B	12.85B	3.4587
LLY Lilly Eli Co	1,009.52	965.26B	65.18B	20.64B	5.96B	22.59
JNJ Johnson Johnson	242.49	595.03B	94.19B	26.80B	19.70B	11.05
ABBV Abbvie Inc	224.81	396.51B	61.16B	4.19B	17.82B	2.3614
AZN Astrazeneca Plc	204.20	323.42B	58.80B	10.24B	8.98B	3.2788
NVS Novartis Ag Adr	162.67	312.78B	54.72B	14.02B	15.32B	7.1855

Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-20-26	Initiated	Barclays	Overweight
Jan-07-26	Upgrade	UBS	Neutral → Buy
Dec-15-25	Upgrade	BofA Securities	Neutral → Buy
Dec-12-25	Upgrade	Guggenheim	Neutral → Buy
Nov-13-25	Initiated	Scotiabank	Sector Perform
Aug-05-25	Downgrade	Daiwa Securities	Outperform → Neutral
Apr-22-25	Initiated	Cantor Fitzgerald	Neutral
Apr-22-25	Initiated	Piper Sandler	Overweight
Dec-16-24	Upgrade	Jefferies	Hold → Buy
Dec-10-24	Resumed	BofA Securities	Neutral
Nov-15-24	Initiated	Wolfe Research	Peer Perform
Nov-13-24	Upgrade	Daiwa Securities	Neutral → Outperform
Nov-12-24	Upgrade	Leerink Partners	Market Perform → Outperform
Oct-25-24	Downgrade	Citigroup	Buy → Neutral
Oct-17-24	Initiated	Bernstein	Mkt Perform
Jul-29-24	Downgrade	Barclays	Overweight → Equal Weight
Mar-11-24	Downgrade	Societe Generale	Buy → Hold
Feb-06-24	Downgrade	Redburn Atlantic	Buy → Neutral
Jan-03-24	Downgrade	BofA Securities	Buy → Neutral
Nov-15-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Nov-09-23	Initiated	Deutsche Bank	Hold
Nov-02-23	Downgrade	Daiwa Securities	Outperform → Neutral
Oct-27-23	Downgrade	BMO Capital Markets	Outperform → Market Perform
Oct-27-23	Upgrade	HSBC Securities	Reduce → Hold
Oct-27-23	Downgrade	William Blair	Outperform → Mkt Perform
Oct-20-23	Resumed	UBS	Neutral
Jul-14-23	Initiated	HSBC Securities	Reduce
Jul-10-23	Initiated	SVB Securities	Market Perform
Jun-28-23	Initiated	Daiwa Securities	Outperform
Mar-06-23	Initiated	Jefferies	Hold
Jan-17-23	Initiated	Cantor Fitzgerald	Overweight
Nov-18-22	Initiated	Credit Suisse	Neutral
Oct-10-22	Downgrade	Guggenheim	Buy → Neutral
Sep-14-22	Downgrade	Berenberg	Buy → Hold
Jun-03-22	Downgrade	Raymond James	Outperform → Mkt Perform
Apr-06-22	Resumed	Morgan Stanley	Underweight
Dec-17-21	Initiated	Goldman	Buy
Dec-09-21	Resumed	Wells Fargo	Equal Weight
Nov-19-21	Initiated	BMO Capital Markets	Outperform
Nov-01-21	Downgrade	Argus	Buy → Hold
Jul-27-21	Resumed	Truist	Buy
Apr-30-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Apr-13-21	Upgrade	Truist	Hold → Buy
Nov-16-20	Upgrade	Societe Generale	Hold → Buy
Nov-10-20	Resumed	Bernstein	Mkt Perform
Nov-06-20	Downgrade	Gabelli & Co	Buy → Hold
Oct-19-20	Upgrade	Guggenheim	Neutral → Buy
Sep-29-20	Initiated	Berenberg	Buy
Jul-28-20	Initiated	Raymond James	Outperform
Apr-02-20	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Mar-23-20	Downgrade	Societe Generale	Buy → Hold
Feb-27-20	Initiated	Barclays	Equal Weight
Jan-06-20	Resumed	Citigroup	Buy
Dec-13-19	Upgrade	Argus	Hold → Buy
Nov-22-19	Resumed	Morgan Stanley	Equal-Weight
Oct-17-19	Resumed	BofA/Merrill	Buy
Aug-14-19	Upgrade	Atlantic Equities	Neutral → Overweight
May-28-19	Initiated	Goldman	Buy
May-20-19	Downgrade	Argus	Buy → Hold
May-03-19	Upgrade	Barclays	Equal Weight → Overweight
May-03-19	Resumed	JP Morgan	Overweight
Jan-15-19	Upgrade	Societe Generale	Sell → Buy
Oct-22-18	Downgrade	Citigroup	Buy → Neutral

View All

Bristol Myers Squibb Co Stock (BMY) Latest News

Feb 21, 2026

This Pfizer Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Friday - Benzinga

Feb 20, 2026

Barclays initiates Bristol-Myers Squibb stock coverage at overweight - Investing.com

Feb 20, 2026

ICICI Prudential Asset Management Co Ltd Grows Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat

Feb 20, 2026

Stem Cell and Regenerative Therapy Markets, 2022-2025 & - GlobeNewswire

Feb 20, 2026

Stem Cell and Regenerative Therapy Markets, 2022-2025 & Forecast to 2030 Featuring Profiles of Leading CompaniesGilead Sciences, Novartis, Bristol-Myers Squibb, Organogenesis, MiMedx Group and More - Yahoo Finance

Feb 20, 2026

Barclays initiates Bristol-Myers Squibb stock coverage at overweight By Investing.com - Investing.com UK

Feb 20, 2026

Feb 19, 2026

Texas sues Sanofi for allegedly 'bribing' providers to boost drug prescriptions - Reuters

Feb 19, 2026

What Does the Street Have to Say About Bristol-Myers Squibb Company (BMY)? - Finviz

Feb 19, 2026

Starton Therapeutics Announces Dosing of First Patient in Phase 2a Study Evaluating STAR-LLD for the Treatment of Multiple Myeloma - GlobeNewswire Inc.

Feb 19, 2026

Feb 18, 2026

Bristol Myers Squibb (NYSE:BMY) Delivers Stability While S&P 500 Stays Volatile - Kalkine Media

Feb 18, 2026

FDA Accepts BMY's NDA for Iberdomide Combo in Multiple Myeloma - Finviz

Feb 18, 2026

Evinova Announces Strategic Collaborations with Astellas, AstraZeneca and Bristol Myers Squibb Advancing Its AI-Native Platform to Accelerate Global Clinical Development - Yahoo Finance

Feb 18, 2026

Bristol-Myers Squibb Co (NYSE:BMY) Offers a High Yield and Durable Dividend for Income Investors - ChartMill

Feb 18, 2026

We Like Bristol-Myers Squibb's (NYSE:BMY) Earnings For More Than Just Statutory Profit - simplywall.st

Feb 18, 2026

FDA accepts BMS protein degrader for review; Disc rare disease drug rejected - Yahoo Finance

Feb 18, 2026

Bristol Myers Squibb Company $BMY Shares Sold by Public Sector Pension Investment Board - MarketBeat

Feb 18, 2026

Feb 17, 2026

Juvenile Idiopathic Arthritis Market is Expected to Expand at a Healthy Growth Rate of 5.6% During the Forecast Period (2026-2036) | DelveInsight – Company AnnouncementFT.com - Financial Times

Feb 17, 2026

Iberdomide FDA Milestone Puts Fresh Focus On Bristol Myers Squibb Hematology - Yahoo Finance

Feb 17, 2026

U.S. FDA accepts Bristol Myers Squibb's NDA for iberdomide in multiple myeloma - marketscreener.com

Feb 17, 2026

Can BMY's Growth Portfolio Counter Legacy Drugs Decline in 2026? - TradingView

Feb 17, 2026

Bristol Myers Squibb gains FDA nod for multiple myeloma drug - Traders Union

Feb 17, 2026

FDA accepts Bristol Myers Squibb’s new drug application for iberdomide - Investing.com

Feb 17, 2026

Vanguard Group Inc. Has $8.84 Billion Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat

Feb 17, 2026

FDA accepts Bristol Myers Squibb’s new drug application for iberdomide By Investing.com - Investing.com Canada

Feb 17, 2026

Bristol-Myers Squibb's Marketing Application for Cancer Therapy Accepted for Review by FDA - marketscreener.com

Feb 17, 2026

U.S. Food and Drug Administration accepts Bristol Myers Squibb's new drug application for iberdomide - marketscreener.com

Feb 17, 2026

Skandinaviska Enskilda Banken AB publ Has $167.77 Million Position in Bristol Myers Squibb Company $BMY - MarketBeat

Feb 17, 2026

Colrain Capital LLC Has $8.03 Million Holdings in Bristol Myers Squibb Company $BMY - MarketBeat

Feb 17, 2026

Feb 16, 2026

Prothena Stock Tumbles 36.8% Year Over Year: What Lies Ahead? - Finviz

Feb 16, 2026

Bristol Myers Squibb Company $BMY Shares Acquired by M&G PLC - MarketBeat

Feb 16, 2026

Bristol Myers Squibb Company $BMY Shares Purchased by State of New Jersey Common Pension Fund D - MarketBeat

Feb 16, 2026

PNC Financial Services Group Inc. Sells 480,848 Shares of Bristol Myers Squibb Company $BMY - MarketBeat

Feb 16, 2026

Shell Asset Management Co. Has $1.52 Million Stake in Bristol Myers Squibb Company $BMY - MarketBeat

Feb 16, 2026

Bristol-Myers Squibb (BMY) Stock Analysis: Is Its 4.15% Dividend Yield Enough for Investors? - DirectorsTalk Interviews

Feb 16, 2026

Feb 15, 2026

Short Interest in Bristol Myers Squibb Company (NYSE:BMY) Drops By 19.1% - MarketBeat

Feb 15, 2026

Berkshire Asset Management LLC PA Trims Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat

Feb 15, 2026

Bristol Myers Squibb Company $BMY Shares Acquired by Aberdeen Group plc - MarketBeat

Feb 15, 2026

Feb 14, 2026